[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eye-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eye-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100597535","a-clinical-study-to-determine-what-effect-the-eyecool-treatment-has-on-the-eyes-surface-anatomy-and-inflammation-response-after-being-treated-for-having-chronic-ocular-surface-pain-cosp-100597535",false,"NCT07059754","A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP)","A Prospective, Feasibility, Single-Center, Clinical Study to Evaluate the Effect of the ETX-4143 Topical Ophthalmic Cooling Device on Ocular Surface Structures and Cell Population in Patients With Chronic Ocular Surface Pain","Inclusion Criteria:\n\n* Documented symptoms of COSP pain for at least 3 months\n* A score of ≥5 on the single question COP-Q Eye Pain Severity Module\n* Able to obtain sufficient quality corneal in-vivo confocal microscopy images\n\nExclusion Criteria:\n\n* Less than 50% improvement in VAS Eye Pain score after topical 0.5% proparacaine hydrochloride at screening\n* Subjects with clinically significant corneal scarring that could limit the confocal microscopy\n* Insufficient number of corneal nerves to permit Fun-IVCM imaging","ALL","22 Years","90 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to understand what effect a cold treatment with an investigational device, ETX-4143, has on the anatomical structures and the inflammatory response of the surface of the eye in those people who suffer from chronic ocular surface pain (COSP). The trial will also tell us more about the safety of this investigational device. The main questions this study aims to answer are:\n\n* What anatomical changes happen to corneal surface nerves after treatment with ETX-4143\n* What changes in inflammatory mediators and cell response take place after treatment with ETX-4143\n\nResearchers will obtain images of the corneal surface nerves for analysis using a confocal microscope and collect tear bio samples for analysis.\n\nParticipants will:\n\n* Be screened for having chronic ocular surface pain\n* Will be treated with ETX-4143 cold treatment for 4 minutes\n* Fill out a weekly questionnaire on eye pain for 12 weeks\n* Be seen in the clinic 2 weeks, 6 weeks, and 12 weeks after treatment to have images of the corneal surface taken, and to collect a tear bio sample",[27],"Eye Pain",[29,30,31,32,33],"Chronic Ocular Surface Pain","Ophthalmic Cooling","Topical Ophthalmic Cooling","Cooling Device","Ocular Surface","RECRUITING","2026-05-21",{"date":37,"type":38},"2026-05-26","ACTUAL",{"date":40,"type":38},"2025-08-25",{"date":42,"type":21},"2026-07-15",{"name":44,"class":45},"EyeCool Therapeutics, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100564070","phase-1-efficacy-and-safety-of-topical-cyclosporine-005-and-lifitgrast-on-the-ocular-surface-symptom-after-photorefractive-keratectomy-in-feiz-hospital-isfahan-2024-100564070","NCT06624384","Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024","Efficacy and Safety of Topical Cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) on the Ocular Surface Symptom After Photorefractive Keratectomy (PRK) in Feiz Hospital, Isfahan, 2024","Inclusion Criteria:\n\nAge above 18 years Myopia and myopic astigmatism The stability of the patients refraction over the past year Not using contact lenses at least 3 weeks before the operation Absence of history of KCN and any type of corneal ectasia in the patient himself or his first degree family No history of previous eye surgery and eye trauma Absence of active eye diseases, corneal dystrophy, retinal diseases, glaucoma, dry eyes of any degree.\n\nAbsence of systemic diseases that can potentially disrupt wound healing, including diabetes, vascular collagen diseases, and pregnancy.\n\nNot taking inhaled or systemic steroids actively or within 3 months before the procedure Absence of anisometropia Not using any systemic and topical analgesia during the last week\n\nExclusion Criteria:\n\nThe patients lack of consent to continue the study Failure to visit the patient for follow-up The occurrence of any complications during the patients surgery","18 Years",{"count":56,"type":21},150,[58],"PHASE1","The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface symptom of patients after PRK. The main questions it aims to answer are:\n\n1- Does the use of cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before photorefractive keratectomy surgery (PRK) reduce ocular surface symptom such as eye pain, redness, and inflammation in conjunctivitis in patients? Researchers will compare cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) to a placebo (Artelac artificial tears) to see if cyclosporine 0.05% and Lifitgrast works to reduce ocular surface symptom.\n\nParticipants will:\n\nTake drug cyclosporine 0.05% and Lifitgrast or a Artelac 30 minutes before surgery Visit the clinic 6 hours, one day, three days and one week after photorefractive keratectomy (PRK) for checkups and tests",[61,62,27,63],"Ocular Surface Symptom","Ocular Surface Disease","Eye Inflammation",[65],"PRK- ocular surface symptom - cyclosporine 0.05% - Lifitgrast (Xiidra)","NOT_YET_RECRUITING","2024-09-30",{"date":69,"type":38},"2024-10-03",{"date":71,"type":21},"2024-10-30",{"date":73,"type":21},"2024-12-30",{"name":75,"class":76},"Mohsen Pourazizi","OTHER"]